AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Alterity Therapeutics Reports Positive Phase 2 Trial Data for ATH434 in Multiple System Atrophy
ByAinvest
Sunday, Aug 17, 2025 2:03 am ET1min read
Alterity Therapeutics Limited (ATHE) announced positive topline data from a Phase 2 trial of ATH434 in multiple system atrophy (MSA). The open-label trial involved 10 patients treated with 75 mg of ATH434 twice daily for 12 months, resulting in a mean increase in UMSARS scores and stability in neurological symptoms for 43% and 30% of participants, respectively. The data supports advancing the ATH434 program in MSA and has the potential to slow disease progression.
Alterity Therapeutics Limited (ATHE) has announced positive topline data from a Phase 2 trial of its oral drug ATH434 in individuals with multiple system atrophy (MSA). The open-label study involved 10 participants diagnosed with the disease, who were treated with 75 mg of ATH434 twice daily for 12 months. The trial demonstrated a mean increase in UMSARS scores and stability in neurological symptoms for 43% and 30% of participants, respectively.The results of the open-label study featured in the press release indicate that ATH434 may have clinical benefits in areas of impairment in MSA, as well as stabilizing biomarkers that underpin the pathology of the disease. The findings compare favorably to a prior study on a similar MSA population.
David Stamler, M.D., Chief Executive Officer of Alterity Therapeutics Limited, commented on the results: "While we acknowledge the potential of ATHE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from..."
The positive topline data from the Phase 2 trial supports the advancement of the ATH434 program in MSA, with the potential to slow disease progression. The trial results are significant for the MSA therapeutic landscape, as the condition is a rare, progressive neurodegenerative disorder with limited treatment options.
References:
[1] https://www.barchart.com/story/news/34058363/multiple-system-atrophy-clinical-trials-companies-therapeutic-assessment-therapies-treatment-algorithm-pipeline-theravance-biopharma-alterity-therapeutics-askbio-kainos-medicines-corestem
[2] https://finance.yahoo.com/news/alterity-therapeutics-limited-athe-announces-055650763.html
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet